Evidence map›Paper›PMID 35098481›Full record

ArticleInternational journal of hematology2022

Bowel wall thickness is a strong predictor of steroid-refractory acute graft-versus-host disease with gut involvement after allo-HSCT.

Mikhail Drokov, Galina Yatsyk, Anna Kireeva, Olga Pirikova, Darya Dubnyak, Larisa Kuzmina, Vera Vasilyeva, Natalia Popova, Olga Starikova, Elena Parovichnikova and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Mikhail DrokovImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation. mdrokov@gmail.com.ORCID http://orcid.org/0000-0001-9431-8316
Galina YatsykMRI and Ultrasonography Department, National Research Center for Hematology, Moscow, Russian Federation.
Anna KireevaMRI and Ultrasonography Department, National Research Center for Hematology, Moscow, Russian Federation.
Olga PirikovaMRI and Ultrasonography Department, National Research Center for Hematology, Moscow, Russian Federation.
Darya DubnyakImmunochemotherapy Department for Patients After BMT, National Research Center for Hematology, Moscow, Russian Federation.
Larisa KuzminaImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation.
Vera VasilyevaImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation.
Natalia PopovaImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation.
Olga StarikovaImmunochemotherapy Department for Patients After BMT, National Research Center for Hematology, Moscow, Russian Federation.
Elena ParovichnikovaImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation.
Valeriy SavchenkoImmunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Novyy Zykovskiy Proezd, d. 4, 125167, Moscow, Russian Federation.
National Medical Research Center for Hematology · RUEndocrinology Research Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAcute graft-versus-host-disease (aGVHD) develops in 10-80% of allo-HSCT patients. More than half of all aGVHD cases are refractory to first-line therapy with steroids. We hypothesized that bowel wall thickness at the time of aGVHD diagnosis could be an early sign of steroid-refractory aGVHD with gut involvement.

methodOur prospective study included 85 patients with hematological malignancies who had undergone allo-HSCT. We used an inexpensive, widespread and simple method of transabdominal ultrasonography to examine bowel wall thickness in patients suspected to have gut aGVHD.

resultsDescending colon wall thickness was significantly greater in patients with gut aGVHD later found to be steroid-refractory than in patients with steroid-sensitive gut aGVHD, with AUC-0.73 (95% CI 0.58-0.87, p = 0.013). We showed that bowel wall thickness could predict the steroid-refractoriness of aGVHD.

conclusionTransabdominal ultrasonography could be used as a marker of steroid-refractory aGVHD with gut involvement after allo-HSCT.

Indexed as

Graft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationAcute DiseaseHumansProspective StudiesSteroidsSteroidsGut aGVHDSteroid refractory GVHDUltrasonography

Identifiers

PMID35098481
OpenAlexW4210765911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.